MGL-3196 is a first-in-class, oral, once-daily, liver-directed, thyroid hormone receptor (THR) β-selective agonist medication that is in Phase 2 development as a treatment for non-alcoholic steatohepatitis (NASH) and heterozygous familial hypercholesterolemia (HeFH). Top-line results from the Phase 2 studies for NASH and HeFH are expected by year-end and in the first quarter of 2018, respectively.
Key findings from the long-term high fat diet (HFD) mouse NASH model include:
- confirmation that prolonged treatment of mice with HFD generates fatty liver disease with a liver gene array profile consistent with activation of NASH inflammation and fibrosis pathways
- findings that MGL-3196 potentially normalizes hepatic function in HFD animals, including restoration of normal hepatic metabolic regulation, liver size and histology without impacting tissues outside the liver
- apparent reversal and prevention of the progression of lipid, inflammatory and fibrotic markers of NASH at human equivalent exposures of MGL-3196
Poster # 1969: MGL-3196, a β-Selective Thyroid Hormone Receptor (THR) Agonist, Demonstrates Metabolic, Anti-inflammatory and Anti-fibrotic Benefits in a Long-term High Fat Diet (HFD) Mouse NASH Model
To view additional upcoming and archived events and presentations, please go to http://www.madrigalpharma.com/newsroom/presentations/
This communication contains “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to, the company's clinical development of MGL-3196, the timing and outcomes of clinical studies of MGL-3196, and the uncertainties inherent in clinical testing. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Madrigal undertakes no obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events. Please refer to Madrigal's filings with the
Source: Madrigal Pharmaceuticals, Inc.